AccuRna Inc. (CEO: Shiro Akinaga, Ph.D., “AccuRna”) today announced the completion of an additional financing round led by UTokyo Innovation Platform Co., Ltd. and Fast Track Initiative, Inc.
With this additional capital, AccuRna will further advance first-in-human clinical study planned with its academic partners and develop its core technologies.
About AccuRna Inc.
AccuRna Inc. has established in December 2015 with a mission to achieve the practical use of the “RNA delivery system”, which is the research result of Prof. Kazunori Kataoka, Professor Emeritus of The University of Tokyo, Director general of Innovation Center of NanoMedicine Kawasaki Institute of Industrial Promotion. The goal of the company is to provide new nucleic acid medicine to patients suffering from underserved diseases with high unmet needs through our internal development effort on pipeline based on aforementioned proprietary platform technology and external collaboration by applying these platform technologies to nucleic acid drug owned by our partners.
Sanyu Bld.201, 3-42-1, Hongo, Bunkyo-ku, Tokyo